Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy- geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 584-590

  Georgakis, Georgios V ^a   Li, Yang ^a   Rassidakis, Georgios Z ^a   Martinez Valdez, Hector ^a   Medeiros, L Jeffrey ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE; CELL PROTEIN; CHAPERONE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DOXORUBICIN; FLICE INHIBITORY PROTEIN; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE ARREST; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOQUINONES; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HODGKIN DISEASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LYMPH NODES; MEMBRANE GLYCOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIFABUTIN; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31544454764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1194     Document Type: Article

References (49)

1. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004;151:1-44.
2. Odunuga OO, Longshaw VM, Blatch GL. Hop: more than an Hsp70/Hsp90 adaptor protein. Bioessays 2004;26:1058-68.
3. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004;562:11-5.
4. Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004;1697:233-42.
5. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-6.
6. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004;9:881-8.
7. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24.
8. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-7.
9. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99.
10. Jackson SE, Queitsch C, Toft D. Hsp90: from structure to phenotype. Nat Struct Mol Biol 2004;11:1152-5.
11. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021-30.
12. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
13. Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17-AAG and beyond. Future Oncol 2005;1:273-81.
14. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90.
15. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-83.
16. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
17. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004;5:19-26
18. Younes A, Carbone A. Clinicopathologic and molecular features of Hodgkin's lymphoma. Cancer Biol Ther 2003;2:500-7.
19. Zheng B, Fiumara P. Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019-27.
20. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15.
21. Wedgwood A, Pro B, Younes A. The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep 2005;4:324-34.
22. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993;9:1-25.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 237-54.
24. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10.
25. Poch G, Reiffenstein RJ, Unkelbach HD. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. Can J Physiol Pharmacol 1990;68:682-8.
26. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci 1996;58:PL23-8.
27. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
28. Rassidakis GZ, Jones D, Thomaides A, et al. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol 2002;118:328-34.
29. Ivy PS, Schoenfeldt M. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG. Oncology (Huntingt) 2004;18:610, 615, 619-20.
30. Altieri DC. Coupling apoptosis resistance to the cellular stress response: the IAP-Hsp90 connection in cancer. Cell Cycle 2004;3:255-6.
31. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005;11:725-30.
32. Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002;158:507-17
33. Cande C, Cohen I, Daugas E, et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002;84:215-22.
34. Kim KM, Lee YJ. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 2005;24:355-66.
35. Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-83.
36. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276:10767-74.
37. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function downregulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
38. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41.
39. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphatidylinositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005;205:498-506.
40. Jucker M, Sudel K, Horn S, et al. Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002;16:894-901.
41. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997;239:655-9.
42. Piatelli MJ, Doughty C, Chiles TC. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J Biol Chem 2002;277:12144-50.
43. Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996;16:5839-45.
44. Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol 2004;201:374-84
45. de Carcer G. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 2004;64:5106-12.
46. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37.
47. Micheau O. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets 2003;7:559-73.
48. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041-52.
49. Dutton A, O'Neil JD, Milner AE, et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci U S A 2004;101:6611-6.